Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Slashed This Year's Revenue Estimates By 17%

The analysts covering Arcus Biosciences, Inc. (NYSE:RCUS) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.

Our free stock report includes 2 warning signs investors should be aware of before investing in Arcus Biosciences. Read for free now.

Following the latest downgrade, the current consensus, from the ten analysts covering Arcus Biosciences, is for revenues of US$128m in 2025, which would reflect an uneasy 9.6% reduction in Arcus Biosciences' sales over the past 12 months. Before the latest update, the analysts were foreseeing US$154m of revenue in 2025. The consensus view seems to have become more pessimistic on Arcus Biosciences, noting the substantial drop in revenue estimates in this update.

View our latest analysis for Arcus Biosciences

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Arcus Biosciences' past performance and to peers in the same industry. We would highlight that sales are expected to reverse, with a forecast 13% annualised revenue decline to the end of 2025. That is a notable change from historical growth of 17% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 17% annually for the foreseeable future. It's pretty clear that Arcus Biosciences' revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The clear low-light was that analysts slashing their revenue forecasts for Arcus Biosciences this year. They also expect company revenue to perform worse than the wider market. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on Arcus Biosciences after today.

Looking for more information? At least one of Arcus Biosciences' ten analysts has provided estimates out to 2027, which can be seen for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.